175 related articles for article (PubMed ID: 32603051)
1. Molecular perspectives for the treatment of hepatocellular carcinoma.
Demory A; Nault JC
Acta Gastroenterol Belg; 2020; 83(2):309-312. PubMed ID: 32603051
[TBL] [Abstract][Full Text] [Related]
2. Advances in molecular classification and precision oncology in hepatocellular carcinoma.
Rebouissou S; Nault JC
J Hepatol; 2020 Feb; 72(2):215-229. PubMed ID: 31954487
[TBL] [Abstract][Full Text] [Related]
3. Molecular profiling of liver tumors: classification and clinical translation for decision making.
Pinyol R; Nault JC; Quetglas IM; Zucman-Rossi J; Llovet JM
Semin Liver Dis; 2014 Nov; 34(4):363-75. PubMed ID: 25369299
[TBL] [Abstract][Full Text] [Related]
4. Integration of genomic information in the clinical management of HCC.
Quetglas IM; Moeini A; Pinyol R; Llovet JM
Best Pract Res Clin Gastroenterol; 2014 Oct; 28(5):831-42. PubMed ID: 25260311
[TBL] [Abstract][Full Text] [Related]
5. TERT promoter mutations in primary liver tumors.
Nault JC; Zucman-Rossi J
Clin Res Hepatol Gastroenterol; 2016 Feb; 40(1):9-14. PubMed ID: 26336998
[TBL] [Abstract][Full Text] [Related]
6. AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation.
Abitbol S; Dahmani R; Coulouarn C; Ragazzon B; Mlecnik B; Senni N; Savall M; Bossard P; Sohier P; Drouet V; Tournier E; Dumont F; Sanson R; Calderaro J; Zucman-Rossi J; Vasseur-Cognet M; Just PA; Terris B; Perret C; Gilgenkrantz H
J Hepatol; 2018 Jun; 68(6):1203-1213. PubMed ID: 29525529
[TBL] [Abstract][Full Text] [Related]
7. Goals and targets for personalized therapy for HCC.
Couri T; Pillai A
Hepatol Int; 2019 Mar; 13(2):125-137. PubMed ID: 30600478
[TBL] [Abstract][Full Text] [Related]
8. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification.
Calderaro J; Couchy G; Imbeaud S; Amaddeo G; Letouzé E; Blanc JF; Laurent C; Hajji Y; Azoulay D; Bioulac-Sage P; Nault JC; Zucman-Rossi J
J Hepatol; 2017 Oct; 67(4):727-738. PubMed ID: 28532995
[TBL] [Abstract][Full Text] [Related]
9. Molecular pathways and related target therapies in liver carcinoma.
Tommasi S; Pinto R; Pilato B; Paradiso A
Curr Pharm Des; 2007; 13(32):3279-87. PubMed ID: 18045179
[TBL] [Abstract][Full Text] [Related]
10. Characterization of pediatric hepatocellular carcinoma reveals genomic heterogeneity and diverse signaling pathway activation.
Haines K; Sarabia SF; Alvarez KR; Tomlinson G; Vasudevan SA; Heczey AA; Roy A; Finegold MJ; Parsons DW; Plon SE; López-Terrada D
Pediatr Blood Cancer; 2019 Jul; 66(7):e27745. PubMed ID: 30977242
[TBL] [Abstract][Full Text] [Related]
11. Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies.
Harding JJ; Nandakumar S; Armenia J; Khalil DN; Albano M; Ly M; Shia J; Hechtman JF; Kundra R; El Dika I; Do RK; Sun Y; Kingham TP; D'Angelica MI; Berger MF; Hyman DM; Jarnagin W; Klimstra DS; Janjigian YY; Solit DB; Schultz N; Abou-Alfa GK
Clin Cancer Res; 2019 Apr; 25(7):2116-2126. PubMed ID: 30373752
[TBL] [Abstract][Full Text] [Related]
12. Molecular Genetics and Targeted Therapy in Hepatocellular Carcinoma.
Marks EI; Yee NS
Curr Cancer Drug Targets; 2016; 16(1):53-70. PubMed ID: 26373716
[TBL] [Abstract][Full Text] [Related]
13. Genetic alterations in hepatocellular carcinoma: An update.
Niu ZS; Niu XJ; Wang WH
World J Gastroenterol; 2016 Nov; 22(41):9069-9095. PubMed ID: 27895396
[TBL] [Abstract][Full Text] [Related]
14. Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas.
Ding X; He M; Chan AWH; Song QX; Sze SC; Chen H; Man MKH; Man K; Chan SL; Lai PBS; Wang X; Wong N
Gastroenterology; 2019 Dec; 157(6):1630-1645.e6. PubMed ID: 31560893
[TBL] [Abstract][Full Text] [Related]
15. Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy.
Dhanasekaran R; Nault JC; Roberts LR; Zucman-Rossi J
Gastroenterology; 2019 Jan; 156(2):492-509. PubMed ID: 30404026
[TBL] [Abstract][Full Text] [Related]
16. RAS/RAF/MEK/ERK, PI3K/PTEN/AKT/mTORC1 and TP53 pathways and regulatory miRs as therapeutic targets in hepatocellular carcinoma.
Akula SM; Abrams SL; Steelman LS; Emma MR; Augello G; Cusimano A; Azzolina A; Montalto G; Cervello M; McCubrey JA
Expert Opin Ther Targets; 2019 Nov; 23(11):915-929. PubMed ID: 31657972
[No Abstract] [Full Text] [Related]
17. Molecular and histological correlations in liver cancer.
Calderaro J; Ziol M; Paradis V; Zucman-Rossi J
J Hepatol; 2019 Sep; 71(3):616-630. PubMed ID: 31195064
[TBL] [Abstract][Full Text] [Related]
18. Next generation sequencing reveals genetic landscape of hepatocellular carcinomas.
Li S; Mao M
Cancer Lett; 2013 Nov; 340(2):247-53. PubMed ID: 23063663
[TBL] [Abstract][Full Text] [Related]
19. Advances in management of hepatocellular carcinoma.
Allaire M; Nault JC
Curr Opin Oncol; 2017 Jul; 29(4):288-295. PubMed ID: 28509806
[TBL] [Abstract][Full Text] [Related]
20. Wnt signaling in hepatocellular carcinoma: analysis of mutation and expression of beta-catenin, T-cell factor-4 and glycogen synthase kinase 3-beta genes.
Cui J; Zhou X; Liu Y; Tang Z; Romeih M
J Gastroenterol Hepatol; 2003 Mar; 18(3):280-7. PubMed ID: 12603528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
